Pricing Log in Create free account

Kairos Pharma, Ltd. (KAPA) vs Propanc Biopharma Inc (PPCB)

Kairos Pharma, Ltd. and Propanc Biopharma Inc are both Biotechnology companies. Kairos Pharma, Ltd. and Propanc Biopharma Inc are of similar size ($1.7M and $1.5M). Across the 11 metrics below, Kairos Pharma, Ltd. leads on 6 and Propanc Biopharma Inc on 5.

Valuation

Metric KAPA PPCB Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 0.36 0.02 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.21 0.00 0.66
EV/Sales n/m n/m 9.02
Earnings yield (399.90%) (6,564.98%) (32.88%)
Free cash flow yield (264.69%) (2,826.85%) (23.13%)

Profitability

Metric KAPA PPCB Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (113.96%) (169.85%) (51.96%)
Return on assets (104.32%) (122.15%) (46.06%)
Return on invested capital (322.91%) (125.86%) 0.00%

Growth

Metric KAPA PPCB Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (30.44%) 95.48% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KAPA PPCB Biotechnology median
Debt to equity 0.00 0.05 0.00
Current ratio 11.98 2.55 4.97
Net debt to EBITDA 1.65 0.02 1.01

Dividend

Metric KAPA PPCB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KAPA PPCB Biotechnology median
Market cap 1.54m 1.69m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack